Sinerem administration

Small molecule

UUniversity of Edinburgh

Sinerem administration is one of 9 small molecule programs targeting Aortic Aneurysm. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Aortic AneurysmActive, not recruiting

Aortic AneurysmPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Aortic Aneurysm

#DrugCompanyPhaseTrials

Diamox

Teva

Approved

1 2

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 3

Circadin

NNeurim Pharmaceuticals Ltd.

Phase 2

—4

Perindopril Arginine

YYaounde Central Hospital

Phase 2

1 5

Cleviprex

Chiesi Farmaceutici S.p.A.

Preclinical

1 6

Sufenta

LLeaf Vertical Inc.

Preclinical

—7

Definity

MMicrovascular Therapeutics, LLC

Preclinical

1 8

Sinerem administration

UUniversity of Edinburgh

Preclinical

1 9

Blood Taking

CCentre Hospitalier Universitaire de Besancon

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Aortic Aneurysm1 trial

Magnetic Resonance Imaging of Aortic Aneurysm Instability

Completed·UUniversity of Edinburgh·Phase 2/3·NCT00794092·29 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Sinerem administration. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sinerem administration compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sinerem administration. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Edinburgh company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: UUniversity of Edinburgh

Sinerem administration

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Aortic Aneurysm1 trial

References

Drug Info

Quick Facts

Related News